加巴喷丁辅助度洛西汀治疗对躯体形式障碍患者HAMD、HAMA评分及认知功能的影响  

Effects of gabapentin assisted treatment with duloxetine on HAMD and HAMA scores and cognitive function in patients with somatoform disorders

作　　者：吴天灵 翟盈 Wu Tian-ling;Zhai Ying(The Seventh Department of Psychiatry,The Fifth People's Hospital of Luoyang,Luoyang 471000,Henan,China)

机构地区：[1]洛阳市第五人民医院精神七科,河南洛阳471000

出　　处：《四川生理科学杂志》2025年第1期153-155,共3页

摘　　要：目的:分析加巴喷丁辅助度洛西汀治疗对躯体形式障碍患者的治疗效果。方法:选取2022年6月至2023年10月期间本院收治的躯体形式障碍患者80例作为研究对象。按照随机数字表法患者分为对照组和观察组,每组各40例。对照组采用度洛西汀治疗,观察组在对照组基础上,加巴喷丁辅助治疗。两组均连续治疗8 w。比较两组的焦虑、抑郁情况、症状改善情况、认知功能和不良反应。结果:治疗后,两组的汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)评分、汉密尔顿抑郁量表(Hamilton depression scale,HAMD)评分均比治疗前显著降低,且观察组的HAMA、HAMD评分较对照组均显著降低(P<0.05)。治疗后,两组的90项症状自评量表(Symptom checklist 90,SCL-90)中抑郁因子、焦虑因子、躯体化因子评分均比治疗前显著降低,且观察组的各项症状评分均较对照组均显著降低(P<0.05)。治疗后,两组的蒙特利尔认知评估量表(Montreal cognitive assessment,MoCA)各项评分均比治疗前显著提高,且观察组的各项认知功能评分均较对照组显著提高(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论:躯体形式障碍患者采用加巴喷丁辅助度洛西汀治疗,能够改善患者的临床症状,提高患者的认知功能,缓解焦虑、抑郁症状,且安全性较好。Objective:To analyze the therapeutic effect of gabapentin assisted treatment with duloxetine on patients with somatization disorder.Methods:80 patients with somatization disorder admitted to our hospital from June 2022 to October 2023 were selected as the research subjects.The patients were divided into the control group and the observation group by random number table method,with 40 patients in each group.The control group was treated with duloxetine,and the observation group was treated with duloxetine assisted by gabapentin.Both groups were treated for 8 weeks continuously.The anxiety,depression,symptom improvement,cognitive function,and adverse reactions of the two groups were compared.Results:After treatment,the Hamilton anxiety scale(HAMA)scores and Hamilton depression scale(HAMD)scores of both groups were significantly lower than those before treatment,and the HAMA and HAMD scores of the observation group were significantly lower than those of the control group(P<0.05).After treatment,the scores of depression,anxiety,and somatization in the Symptom checklist 90(SCL-90)of both groups were significantly lower than those before treatment,and the scores of all symptoms in the observation group were significantly lower than those of the control group(P<0.05).After treatment,the Montreal cognitive assessment(MoCA)scores of both groups were significantly higher than those before treatment,and the cognitive function scores of the observation group were significantly higher than those of the control group(P<0.05).The incidence rates of adverse reactions in the two groups were not significantly different(P>0.05).Conclusion:The treatment of somatization disorder patients with gabapentin assisted duloxetine can improve their clinical symptoms,improve their cognitive function,alleviate anxiety and depression symptoms,and have good safety.

关 键 词：躯体形式障碍 度洛西汀 加巴喷丁 心理状态 认知功能 

分 类 号：R749[医药卫生—神经病学与精神病学]